It is important to mention that RUNX1 was not altered, neither transcriptionally nor molecularly, since all exons of the gene were studied in the mice with the aberrant population and none presented somatic mutations in the healthy allele of RUNX1, which is considered the second most frequent event in the development of FPD/AML. This evidence concerns the gene RUNX1 and acute myeloid leukemia.